Novavax's Updated COVID-19 Vaccine Receives FDA Authorization and Recommendation
Novavax's protein-based COVID-19 vaccine, Adjuvanted (2023-2024 Formula), has received Emergency Use Authorization (EUA) from the FDA and has been recommended by the CDC for individuals aged 12 and older. This authorization makes Novavax's vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. Doses will be available at thousands of locations across the country in the coming days. The vaccine has shown immune responses against multiple variants and has reported common side effects such as headache and fatigue. Novavax is working with global regulatory authorities for further authorizations.